期刊文献+

亚胺培南西司他丁治疗重症肺炎患者的观察 被引量:23

Clinical observation of Tienam in treating patients with severe pneumonia
下载PDF
导出
摘要 目的评价亚胺培南西司他丁治疗重症肺炎患者的临床疗效及安全性。方法以42例重症肺炎患者为研究对象,给予亚胺培南西司他丁0.5或1 g,q8 h静滴,观察重症肺炎患者的临床和不良反应。结果应用亚胺培南西司他丁治疗重症肺炎患者的疗效明显胜于治疗前;痰液病原体的清除率为87.5%;胸部CT肺部炎性渗出病灶较前明显吸收;34例存活的重症肺炎患者未见不良反应。结论亚胺培南西司他丁对重症肺炎患者有良好的治疗效果。 Objective To evaluate clinical efficacy and safety of Tienam in treating patients with severe pneumonia. Methods 42 cases of patients with severe pneumonia were selected as subjects who were given Tienam 0.5 or 1 g, q8 h intravenously for 9.5 ( ± 2. 5) days. Body temperature change was observed, serum high-sensitivity C-reactive protein, blood routine test, alanine aminotransferase ( ALT ) , aspartate aminotransferase (AST) , blood urea nitrogen ( BUN ) , creatinine (Cr) , arterial blood oxygen pressure ( PaO2 ) and oxygenation index(PaO2/FiO2 )were detected before and after the treatment,sputum culture was carried out, chest CT was reviewed in the subjects. Differences of related values were compared before and after the treatment,adverse reaction of Tienam was observed in the subjects. Results The main findings were as followes : Serum high-sensitivity C-reactive protein concentration after the treatment [ (9. 1 ±3.1 ) mg/ L ] was significantly lower than that before the treatment [ ( 97.6 ±21.3 ) mg/L ] ; total number of peripheral white blood cells after the treatment[ (5.8 ± 2.5) ×10^9/L] was significantly lower than that before the treatment [ (18. 3 ± 6. 2 ) × 10^9/L] ;PaO2 after the treatment [ (85.2± 10. 2)mmHg] was significantly higher than that before the treatment[ (52. 3 ± 14.4)mmHg] ; PaO2/FiO2 after the treatment [ (411.6 ± 57.1 )mmHg] was significantly higher than that before the treatment [ (265.6 ± 29.3 )mmHg] ;all with obviously statistical significance in differences( P 〈 0. 01 ) for patients with severe pneumonia. There were no statistical differences( P 〉 0.05 ) on ALT, AST, BUN and Cr before and after the treatment. Sputum pathogen clearance rate was 87.5%. Inflammatory exudation in lungs of chest CT were obviously absorbed after the treatment. No adverse reaction was observed in 34 cases of survivors with severe pneumonia. Conclusion Tienam has good therapeutic effect for patients with severe pneumonia.
作者 施炜 熊伟
出处 《临床肺科杂志》 2010年第5期625-626,共2页 Journal of Clinical Pulmonary Medicine
关键词 亚胺培南西司他丁 重症肺炎 治疗 tienam severe pneumonia treatment
  • 相关文献

参考文献5

  • 1Mandell LA,Wunderink RG,Anzueto A,et al.Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.Clin Infect Dis,2007,44(Suppl 2):27-72.
  • 2王志勇,廖镇江,夏照帆,陈国华,寿永明,李永林,林才.美罗培南治疗中、重度烧伤感染的临床观察[J].中国感染与化疗杂志,2007,7(3):191-193. 被引量:4
  • 3Alvarez Lerma F,Serious Infection Study Group.Efficacy of Tienam as monotherapy in the treatment of ventilator-associated pneumonia.J Chemother,2001,13(1):70-81.
  • 4易慧,谢灿茂.重症肺炎临床及预后因素分析[J].中华医院感染学杂志,2008,18(1):56-58. 被引量:106
  • 5Hughes WT,Armstrong D,Bodey GP,et al.2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.Clin Infect Dis,2002,34(6):730-751.

二级参考文献18

  • 1黄仲义.美罗培南的药理学和临床应用[J].中国新药与临床杂志,2005,24(12):971-973. 被引量:16
  • 2牟小芬,张进川,夏文俊.长期机械通气的老年患者医院内肺部感染的调查[J].中华医院感染学杂志,2006,16(5):500-502. 被引量:18
  • 3孙树梅,李琼,王茵茵,张亚莉,汪能平.发生呼吸机相关性肺炎的高危因素及病原菌分析[J].中华医院感染学杂志,2006,16(8):882-884. 被引量:87
  • 4[1]American Thoracic Society.Guidelines for the management of adults with community acquired pneumonia[J].Am J Crit Care Med,2001,163(7):1730-1754.
  • 5[2]American Thoracic Society,Infectious Diseases Society of America.Guidelines for the management of adults with hospital-acquired,ventilator-associated,and healthcare-associated pneumonia[J].Am J Respir Crit Care,2005,171(4):388-416.
  • 6[3]Paganin F,Lilienthal F,Bourdin A,et al.Severe community-acquired pneumonia:assessment of microbial aetiology as mortality factor[J].Eur Respir J,2004,24(5):779-785.
  • 7[4]Rello J,Bodi M,Mariscal D,et al.Microbiological testing and outcome of patients with severe community-acquired pneumonia[J].Chest,2003,123(1):174-180.
  • 8[7]Valles J,Mesalles E,Mariscal D,et al.A 7-year study of severe hospital-acquired pneumonia requiring ICU admission[J].Intensive Care Med,2003,29(11):1981-1988.
  • 9[8]Wilson PA,Ferguson J.Severe community-acquired pneumonia:an Australian perspective[J].Intern Med J,2005,35(12):699-705.
  • 10[9]Martinez JA,Horcajada JP,Almela M,et al.Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia[J].Clin Infect Dis,2003,36(4):389-395.

共引文献107

同被引文献169

引证文献23

二级引证文献177

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部